VolitionRx Limited (VNRX)
- Previous Close
0.7728 - Open
0.7400 - Bid --
- Ask 0.8700 x 1000
- Day's Range
0.7000 - 0.7675 - 52 Week Range
0.4300 - 1.2300 - Volume
51,033 - Avg. Volume
145,378 - Market Cap (intraday)
64.471M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4000 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.27
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
www.volition.com101
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: VNRX
View More
Performance Overview: VNRX
Trailing total returns as of 10/9/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VNRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VNRX
View MoreValuation Measures
Market Cap
64.47M
Enterprise Value
64.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
57.77
Price/Book (mrq)
--
Enterprise Value/Revenue
65.88
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-100.82%
Return on Equity (ttm)
--
Revenue (ttm)
976.52k
Net Income Avi to Common (ttm)
-32.42M
Diluted EPS (ttm)
-0.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
6M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.7M
Research Analysis: VNRX
View MoreCompany Insights: VNRX
VNRX does not have Company Insights